Citations

Clear

6273 citation(s) found for "To, Andrew".

Molecular classification of radiation-induced meningiomas
Ellenbogen, Yosef , Patil, Vikas, Landry, Alexander , Yefet, Leeor S. , Wang, Justin, Ajisebutu, Andrew, Chloe, Gui, Persaud, Phooja, Aldape, K., Nassiri, Farshad, Zadeh, Gelareh, Aldape, Kenneth D, Ellenbogen, Yosef , Patil, Vikas , Gui, Chloe , Liu, Jeff , Nassiri, Farshad , Zadeh, Gelareh

Mayo Clinic

International Journal of Radiation Biology | February 2, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-7

10.1080/09553002.2026.2618533 | PMID 41628362 Get It

Uncovering the genetic landscape of cholangiocarcinoma and its subtypes via GWAS and integrative analyses
Han, Younghun , Byun, Jinyoung, Cooley, Matthew A. , Shaw, Vikram R., Ahmed, Fowsiyo , Giama, Nasra H., Ali, Hawa M. , Campbell, Nellie A. , Hassan, Mohamed, Andersen, Jesper B., Ankoma-Sey, Victor, Bañales, Jesús M. , Bujanda, L. , Bathe, Oliver F. , Bekaii-Saab, Tanios S., Borad, Mitesh J., Chan, Carlos H.F. , Cleary, S., Folseraas, Trine , Galle, P R, MacInnis, Robert J., Gores, Gregory J., Houlston, Richard S., Ilyas, Sumera, Javle, Milind, Johansen, Julia S., Christensen, Troels Dreier , Kamath, Ashwin S. , Kelley, Robin Kate , Lamarca, Angela, Lammert, F, Lindsey, Stacie , Macias, Rocio I. R., Patel, Tushar, Permuth, Jennifer B., Rossi, Stephen, Sanchez, William, Smoot, Rory L., Swerdlow, Anthony J., Cao, H. Tran, Valle, Juan, Weinmann, A., Wong, Linda L. , Zimmer, Vincent, Zhu, A., Kn, Lazaridis, Juran, Brian D., Jalal, Prasun Kumar, Knox, J., Hutchinson, Amy, Hicks, Belynda, Chanock, Stephen J., Hassan, Manal M. , Amos, Christopher I., McGlynn, Katherine A., Roberts, Lewis R., Roberts, Lewis R. , Sánchez, William , Han, Younghun , Byun, Jinyoung , Byun, Jinyoung , VanLith, Caitlin J. , Roberts, Lewis R , Banales, Jesus M , Jalal, Prasun K , Chan, Carlos H F , Sanchez, William , Shaw, Vikram R. , Hatia, Rikita , Andersen, Jesper B , Ankoma‐Sey, Victor, Bekaii‐Saab, Tanios , Borad, Mitesh J. , Björkström, Niklas K. , Cleary, Sean P. , Cornillet, Martin , Galle, Peter R., Genkinger, Jeanine M. , MacInnis, Robert J. , Gores, Gregory J. , Goyal, Lipika , Houlston, Richard S. , Ilyas, Sumera I. , Javle, Milind , Johansen, Julia S., Khan, Shahid Ali , Kim, Richard D. , Kwee, Sandi Alexander , Lamarca, Angela , LaRusso, Nicholas F. , Malhi, Harmeet , Permuth, Jennifer B. , Reeves, Helen L. , Smoot, Rory L. , Swerdlow, Anthony J , Weinmann‐Menke, Julia , Zhang, Xuehong , Zimmer, Vincent , Zhu, Andrew X. , Jalal, Prasun K. , Hutchinson, Amy , Hicks, Belynda , Koshiol, Jill , Chanock, Stephen Jacob , Amos, Christopher I. , McGlynn, Katherine A.

Mayo Clinic

Hepatology | February 2, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/hep.0000000000001699 | PMID 41627892 Get It

Background and Aims: Cholangiocarcinoma (CCA) is a rare but aggressive malignancy with poorly understood genetic susceptibility. To date, genome-wide association studies (GWAS) investigating germline variants associated with CCA risk remain limited. We aimed to identify genetic risk loci for CCA and its clinical subtypes through comprehensive GWAS and post-GWAS analyses. Approach and Results: We conducted a GWAS of 2366 CCA cases and 11,750 controls of European ancestry. Genome-wide significant loci ( p <5×10 −8 ) were identified and further examined through fine-mapping, functional annotation, and HLA imputation. Subgroup analyses were conducted by CCA subtypes and primary sclerosing cholangitis (PSC) status. Cross-trait linkage disequilibrium score regression and Mendelian randomization were employed to investigate the shared genetic architecture and potential causal relationships with a diverse range of traits. We identified 1 new genome-wide significant variant, rs535777 (OR=1.44), near HLA-DRB1/DQA1 associated with CCA, and 2 variants associated with extrahepatic CCA: rs116224263 (OR=0.17) in LINC02506 at 4p15.1 and rs6914950 (OR=1.63) near HLA-DRB1/DQB1 . Stratified analyses revealed rs2395184 (OR=3.51) near HLA-DRA/DRB5 associated with PSC-related CCA, and rs142674434 (OR=2.98) in THSD7A at 7p21.3 associated with non-PSC-related CCA. HLA imputation uncovered new amino acid residues associated with disease risk. Cross-trait analyses identified shared genetic signals between CCA and anthropometric, lipidemic, lifestyle, and medical traits. Mendelian randomization supported putative causal associations for 12 traits with CCA or its subtypes. Conclusions: Our large-scale GWAS highlights new genetic variants and HLA-linked mechanisms underlying CCA susceptibility. Integrating multi-step post-GWAS approaches enhances understanding of CCA pathogenesis and may facilitate the development of risk biomarkers for early detection and precision prevention strategies.
Robot‐assisted ultrasound‐guided PCNL : initial experience in 10 consecutive cases
Amenyogbe, Andrew , Humphreys, Mitch, Cabo, Jackson , Stern, Karen , Cabo, Jackson , Stern, Karen L

Mayo Clinic

BJU International | January 31, 2026 | Volume: 137 | Issue: 5 | Pages: 788-790

10.1111/bju.70162 | PMID 41618629 Get It

Multicenter Evaluation of Myocardial Flow Reserve as a Prognostic Marker for Mortality in 13 N-Ammonia PET Myocardial Perfusion Imaging
Ramirez, Giselle, Builoff, Valerie , Miller, R., Lemley, Mark , Carvajal-Juarez, Isabel, Alexanderson, Erick, Rosamond, Thomas, Song, Na , Travin, Mark I. , Slipczuk, Leandro, Wopperer, Samuel, Carli, Marcelo F. Di, Chareonthaitawee, Panithaya, Slomka, Piotr J, Slipczuk, Leandro , Miller, Robert J.H. , Carvajal-Juarez, Isabel , Miller, Robert J H , Carvajal-Juarez, Isabel , Slipczuk, Leandro , Einstein, Andrew Jeffrey , Wopperer, Samuel B., Di Carli, Marcelo F , Chareonthaitawee, Panithaya , Slomka, Piotr J , Lemley, Mark , Alexanderson, Erick , Wopperer, Samuel, Carli, Marcelo F. Di , Chareonthaitawee, Panithaya

Mayo Clinic

Circulation: Cardiovascular Imaging | January 30, 2026 | Volume: 19 | Issue: 4 | Pages: No page available

10.1161/circimaging.125.018729 | PMID 41614241 Get It

BACKGROUND: Myocardial flow reserve (MFR), measured by positron emission tomography (PET) myocardial perfusion imaging, provides valuable information on epicardial coronary disease, diffuse atherosclerosis, and microvascular function. Despite its routine use, the prognostic efficacy of 13 N-ammonia PET MFR remains unconfirmed in larger multicenter cohorts of patients with suspected or known coronary artery disease. METHODS: We considered patients from 5 sites in the REFINE PET (Registry of Flow and Perfusion Imaging for Artificial Intelligence with PET) registry who underwent 13 N-ammonia PET myocardial perfusion imaging for coronary artery disease. Clinical and imaging data were collected at the time of myocardial perfusion imaging. MFR was quantified as the ratio of stress to rest myocardial blood flow, using QPET software (Cedars-Sinai Medical Center, Los Angeles, CA). The primary outcome was all-cause mortality. Survival analyses were performed using Kaplan-Meier and Cox regression models adjusted for clinical and imaging covariates. RESULTS: In total, 6277 patients were included (median age of 65 years, 56% male). Median follow-up time was 3.8 years. There were 1895 patients with MFR ≤2 and 4382 with MFR >2. Patients with MFR ≤2 had significantly higher mortality than those with MFR >2 (n=701 [37.0%] versus n=537 [12.3%], respectively; P <0.001). Annualized all-cause mortality rates by MFR and summed stress score ranged from 1.7 to 15.8. In multivariable analysis, MFR ≤2 was independently associated with increased all-cause mortality in the overall population (hazard ratio, 2.70 [95% CI, 2.41–3.03]; P <0.001), even among patients with no perfusion defects (hazard ratio, 2.36 [95% CI, 1.93–2.89]; P <0.001). Mortality risk decreased across increasing MFR deciles, ranging from hazard ratio, 2.73 (95% CI, 2.39–3.11) to hazard ratio, 0.35 (95% CI, 0.25–0.49). CONCLUSIONS: In this large multicenter cohort, MFR derived from 13 N-ammonia PET myocardial perfusion imaging is a strong, independent predictor of all-cause mortality, even in patients with normal perfusion. An MFR of ≤2 identifies elevated risk, while higher values are associated with improved survival. These findings support the routine integration of MFR to enhance risk stratification in patients with suspected or known coronary artery disease.
Long-term cellular and humoral responses to SARS-CoV-2 vaccinations in patients with solid malignancies undergoing chemotherapy
liu, Andrew, Necela, Brian, Li, Zhuo, Cogen, Davitte , Wieczorek, Mikolaj A. , Mummareddy, Ashita , Acampora, Marites, Reynolds, Gina, Advani, Pooja , Moreno-Aspitia, Alvaro, Virk, Abinash, Bharucha, A E, Marquez, Christopher P. , Patel, Tushar C., Knutson, KL, Chumsri, Saranya , Li, Zhuo , Reynolds, Gina A, Advani, Pooja P, Necela, Brian M. , Mummareddy, Ashita , Swift, Melanie D. , Virk, Abinash , Bharucha, Adil E. , Knutson, Keith L.

Mayo Clinic

Frontiers in Immunology | January 29, 2026 | Volume: 16 | Issue: No issue available | Pages: No page available

10.3389/fimmu.2025.1690495 | PMID 41693712 Get It

Background While SARS-CoV-2 vaccines are highly effective in healthy individuals, the magnitude and durability of humoral and cellular responses in patients with solid malignancies receiving chemotherapy remain understudied. Previous reports suggest that patients with cancer may not mount adequate immune response after SARS-CoV-2 vaccination. Additionally, most studies focused on humoral responses, while data regarding cellular immune responses are scarce. In this study, we evaluated humoral and cellular responses in patients with solid tumors receiving chemotherapy compared to healthy individuals up to one year after vaccinations. Methods Patients aged ≥18 who were willing to receive the SARS-CoV-2 vaccine were enrolled. Anti-SARS-CoV-2 immunoassays were used to detect antibodies against nucleocapsid and spike proteins. Human IFN-γ Fluorospot assay was used to determine antigen−specific T-cell responses. Data were compared between groups using Mann−Whitney test for continuous variables and Fisher’s exact test for categorical variables. Results A total of 67 subjects (47 patients with cancer and 20 healthy individuals) were included. 1–3 months following the second vaccine doses, 96% of patients with cancer and 100% of healthy individuals demonstrated a positive humoral response. While the positivity rate was not significantly different, patients with cancer had significantly lower spike IgG antibodies than healthy individuals. However, this difference diminished at 6 months when patients with cancer had increased antibodies compared to decreased antibodies in the healthy cohort and no difference was noticed at 12-month. Patients with cancer developed a similar antigen-specific T-cell response as healthy individuals at 1–3 months, 6 months and 12 months. There were no significant differences when comparing patients aged ≤ 55 years vs. &gt;55 years, stages I-III vs. IV, single vs. multiple chemotherapy, and BNT162b2 vs. mRNA-1273 vaccines. There was a significant moderate correlation between neutralization and antibody levels at 12 months. However, despite patients with cancer having a significantly higher COVID risk score, there were no significant differences in COVID-19 infection and hospitalization between patients with cancer and healthy individuals. Conclusion Despite initial impaired antibody responses to SARS-CoV-2 vaccinations, patients with solid malignancies receiving chemotherapy effectively generated long-term cellular and humoral responses by 6 and 12 months, leading to similar infection and hospitalization rates compared to healthy individuals.
Urine Proteomics Identifies Biomarkers for Diagnosis and Fibrosis Severity in Pediatric Chronic Pancreatitis
Moore, Madalyn G., Garlapally, Vineet , Brusach, Katelyn B., Babcock, Lynn , Gurría, Juan P. , Saad, Michelle , Zhang, L, Cruz-Monserrate, zobeida, Abu-El-Haija, Maisam, Searle, Brian C , Brusach, Katelyn B, Akshintala, Venkata S. , Hornung, Lindsey N. , Sheridan, Rachel M. , Trout, Andrew T. , Cruz‐Monserrate, Zobeida , Searle, Brian C. , Abu‐El‐Haija, Maisam

Mayo Clinic

Clinical and Translational Gastroenterology | January 28, 2026 | Volume: 17 | Issue: 3 | Pages: e00981

10.14309/ctg.0000000000000981 | PMID 41604167 Get It

INTRODUCTION: Reliable biomarkers for the diagnosis of chronic pancreatitis (CP) and pancreatic fibrosis severity are lacking, hindering effective treatment and management. Histologic fibrosis is a hallmark of late-stage CP, but noninvasive methods to evaluate fibrosis progression are limited. We used urine proteomics to discover biomarkers that identify patients with CP and predict fibrosis severity. METHODS: We performed a cross-sectional study of 130 total subjects (CP n = 50) selected based on clinical criteria in a tertiary care setting. Urine proteomics samples were quantified using data-independent acquisition mass spectrometry. Differential biomarker candidates were identified with false discovery rate-corrected pairwise comparisons. These proteins were validated with an independent paired urine and plasma sample cohort (n = 36). Machine learning was used to develop a protein panel that predicted Ammann scores for patients with histologic fibrosis. RESULTS: We found 34 proteins consistently differentially expressed between CP and controls in pairwise false discovery rate-controlled tests. Of these, 25 urine proteins outperformed 19 previously suggested CP blood-based biomarkers in an independent validation cohort. Isocitrate dehydrogenase (IDH1), calcyphosin (CAPS), synuclein gamma (SNCG), and protein S100-P (S100P) all produced receiver operator curve area under the curve values >0.95, while the best plasma marker was interleukin 2 receptor subunit alpha (receiver operator curve area under the curve = 0.80). A 12-protein panel of identified markers predicted fibrosis severity with a linear correlation R 2 value of 0.61. DISCUSSION: We identified a panel of proteins that may diagnose CP in children and developed a model to predict pancreatic fibrosis severity, offering promising tools for improving diagnostics and patient care.
Accuracy of the Garmin Vivoactive 4 for Estimating Heart Rate, Energy Expenditure, and Step Count During Treadmill Exercise
Leon, Matteo F. de, Camic, Clayton L., Kowal, Rachel A., Aldape, Brittney, Lochbaum, Brendan, Stefan, Riley, Chomentowski, Peter J., Jagim, Andrew R. , Male, Brandon M., Jagim, Andrew R , Leon, Matteo F. de , Kowal, Rachel A., Aldape, Brittney, Lochbaum, Brendan, Stefan, Riley R., Male, Brandon

Mayo Clinic

Applied Sciences | January 27, 2026 | Volume: 16 | Issue: 3 | Pages: 1286

10.3390/app16031286 Get It

The purpose of this study was to examine the validity of a Garmin device for estimating heart rate, energy expenditure, and step count during incremental treadmill exercise. Eighteen physically active males (n = 12; mean ± SD age = 22.8 ± 4.7 years; body mass = 83.8 ± 13.4 kg) and females (n = 6; 24.2 ± 5.6 years; 65.2 ± 9.6 kg) completed an incremental treadmill test with the Garmin Vivoactive 4 and criterion methods measuring heart rate, energy expenditure, and step count. Mean absolute percent error (MAPE) and Bland–Altman plots were used to assess accuracy. Acceptable accuracy was defined as MAPE < 5% for heart rate and <10% for energy expenditure and step count. MAPE (±SD) values were 13.0 (±10.1), 19.1 (±15.0), and 4.6 (±5.3)% for heart rate, energy expenditure, and step count, respectively. The Bland–Altman regression analyses illustrated proportional bias was present for heart rate (r = 0.591, p < 0.001) and step count (r = 0.516, p = 0.028), but not energy expenditure (r = 0.351, p = 0.153). These findings indicated that the Garmin Vivoactive 4 provided acceptable accuracy for step count but unacceptable accuracy for heart rate and energy expenditure during incremental treadmill exercise.
Alliance A222001: Oxybutynin Versus Placebo for the Treatment of Hot Flashes in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer
Stish, Bradley J. , Mazza, Gina L. , Nauseef, Jones T. , Humeniuk, Michael, Smith, Thomas J. , Tofthagen, Cindy, Pardo, D.A. Diaz, Chay, Christopher H., Huang, Andrew Jonathan, Naha, Kushal , Tagawa, Scott T., Chow, Selina , Ruddy, Kathryn, Lustberg, Maryam B. , Adams-Campbell, Lucile L., Novotny, Paul J. , Loprinzi, Charles L. , Tofthagen, Cindy , Diaz, Dayssy A. , Tofthagen, Cindy S , Sebastian, Nikhil T , Huang, Andrew J , Tagawa, Scott T , Ruddy, Kathryn J , Smith, Thomas J , Mazza, Gina L , Nauseef, Jones T , Lustberg, Maryam , Tagawa, Scott T. , Ruddy, Kathryn J. , Adams-Campbell, Lucile L.

Mayo Clinic

Journal of Clinical Oncology | January 26, 2026 | Volume: 44 | Issue: 13 | Pages: 1198-1205

10.1200/jco-25-01486 | PMID 41587370 Get It

PURPOSE Hot flashes are a common side effect reported by men receiving androgen-deprivation therapy (ADT) for the treatment of prostate cancer. We sought to determine whether oxybutynin could improve hot flash symptoms in men with prostate cancer. PATIENTS AND METHODS Patients with prostate cancer receiving a stable regimen of ADT with at least 28 hot flashes per week were randomly assigned to receive either oxybutynin 2.5 mg twice daily, oxybutynin 5 mg twice daily, or matching placebo for 6 weeks. The primary end point was the change in patient-reported hot flash scores since baseline at 6 weeks. Additional outcomes included incidence of adverse events (AEs), changes since baseline in Hot Flash–Related Daily Interference Scale (HFRDIS) scores, and patient-reported symptoms. RESULTS Eighty-eight patients were enrolled, with the 81 participants eligible for final analysis reporting an average of 10.1 (standard deviation [SD], 5.55) hot flashes per day and an average daily hot flash score of 18.2 (SD, 13.5) included in final analysis. On average, patients on the placebo arm, 2.5 mg oxybutynin arm, and 5 mg oxybutynin arm had reductions in hot flashes/day of 2.15, 4.77 ( P = .02), and 6.89 ( P < .001), respectively. Daily hot flash scores for placebo, 2.5 mg oxybutynin, and 5 mg oxybutynin reduced by an average of 4.85, 9.94 ( P = .07), and 13.95 ( P = .002) points, respectively. No treatment-related grade 3+ AEs occurred. HFRDIS total scores improved by 14.2 and 20.7 points in the 2.5 mg ( P = .042) and 5 mg ( P < .01) oxybutynin arms, respectively, compared with a 3.1-point improvement with placebo. CONCLUSION Oxybutynin is superior to a placebo for the management of ADT-associated hot flashes in men with prostate cancer.
Outcomes for Sinonasal Undifferentiated Carcinoma (SNUC): An International Multi-Center Retrospective Cohort Study
Liu, Jacklyn , Takahashi, Yoko , Rehman, Umar , Turri-Zanoni, Mario, Mattavelli, Davide, Counsell, Nicholas , Ferrari, Marco, Rampinelli, Vittorio , Vermi, William , Lombardi, Davide , Saade, Rami , Park, Ki Wan , Emanuel, Oscar , Schartinger, Volker Hans , Franchi, Alessandro , Facco, Carla, Sessa, Fausto, Battocchio, Simonetta , Eriksen, Patrick René Gerhard , Haddouchi, Mohamed El, Maragliano, Roberta , Lelkaitis, Giedrius , Saraswathula, Anirudh, KAUR, RAMAN PREET, Mydlarz, Wojciech K. , Ishii, Masaru, Dave, Manas, Fenton, Tim R. , Lim, Alison E. , Okhovat, Saleh , Elegio, Gyleen, Pouvreau, Pierre, Thariat, Juliette, Digue, L., Ferrand, François-Régis, Costes-Martineau, Valerie, Castain, Claire, Kermadec, H. De , O’Neill, James Paul, Lacy, Peter D., Vaz, Francis, O’Flynn, Paul, Howard, David J., Stimpson, Paul, Wang, S, Royle, Gary , Steele, Christopher, Jay, A., Carnell, Dawn , Forster, Martin D., Thomson, David, Buchwald, Christian von, Lllorente, Jose Luis, Hermsen, Mario A., Jurmeister, Philipp , Capper, David, Gallia, Gary L. , Js, Tay, Mohyeldin, Ahmed, Fernandez-Miranda, Juan, LE, Q, West, Robert B., Patel, Z M, Hwang, P H, Facchetti, Fabio , Nicolai, Piero, Ferrarotto, Renata, Phan, Jack, Bossi, P., Castelnuovo, P., Moya-Plana, Antoine, Verillaud, B., Garnis, Cathie , Thamboo, Andrew , Olawuni, Felicia O., Moore, E.J., Choby, Garret M., Lal, Devyani, Akhave, Neal S. , Bell, Diana , Su, Shirley Y., Lund, Valerie J., London, Nyall R. , HANNA, Ehab, Lechner, Matt, Hwang, Peter H. , Thariat, Juliette , Phan, Jack , Le, Quynh‐Thu , Patel, Zara M. , Franchi, Alessandro , Su, Shirley Y. , Lund, Valerie J. , Lechner, Matt , Castelnuovo, Paolo , Ferrari, Marco , Turri‐Zanoni, Mario , Mattavelli, Davide , Moya‐Plana, Antoine , Rehman, Umar , Turri-Zanoni, Mario , Mattavelli, Davide , Ferrari, Marco , Schartinger, Volker H , Maragliano, Roberta , Lelkaitis, Giedrius , Fenton, Tim R , Thariat, Juliette , Ferrand, Francois-Regis , Howard, David J , Carnell, Dawn , Forster, Martin D , von Buchwald, Christian , Hermsen, Mario , Tay, Joshua K , Le, Quynh-Thu , Patel, Zara , Hwang, Peter H , Facchetti, Fabio , Phan, Jack , Bossi, Paolo , Castelnuovo, Paolo , Moya-Plana, Antoine , Olawuni, Felicia, Su, Shirley Y , Lund, Valerie J , Lechner, Matt , Sessa, Fausto , Bendtsen, Simone K. , Jakobsen, Kathrine Kronberg , Saraswathula, Anirudh , Ramanathan, Murugappan , Ishii, Masaru, Dupin, Charles Louis , Digue, Laurence, Costes‐Martineau, Valérie , Castain, Claire , Hintze, Justin , O'Flynn, Paul E., Steele, Christopher D. , Woods, Robbie , Llorente Pendás, José Luis , Capper, David , Nayak, Jayakar V. , Nicolai, Piero , Vérillaud, Benjamin , Choby, Garret , Hanna, Ehab Y.

Mayo Clinic

Cancers | January 26, 2026 | Volume: 18 | Issue: 3 | Pages: 366

10.3390/cancers18030366 | PMID 41681839 Get It

Background: Sinonasal undifferentiated carcinoma (SNUC) is an extremely rare, high-grade, and aggressive tumor of the sinonasal tract. Due to the rarity of this malignancy, current treatment guidelines are based on small and often/mainly single-center retrospective datasets. In the absence of a universally accepted standard of care for SNUC, treatment approaches vary across countries and institutions, reflecting real-world clinical practice. The primary aim of this study was to describe real-world treatment and outcomes for patients with confirmed SNUC. Methods: This was an international, multi-center, retrospective, observational cohort study that pooled patients into the largest SNUC dataset to date. Fifteen centers were enrolled to contribute data, including seven from Europe, four from the United States, three from the United Kingdom, and one from Canada. In the absence of a universally accepted standard of care for SNUC, treatment approaches varied across countries and institutions, reflecting real-world clinical practice. Patients included were those with histologically confirmed SNUC who were treated between 1997 and 2021. Results: This study yielded 485 patients treated for SNUC. The median age at diagnosis was 55.6 years (IQR: 44.5–67.6), and 63.7% were male. Most cases presented at advanced stages, with 70.8% as T4a or T4b. Overall survival (OS) outcomes were available for 412 patients, with a median follow-up of 26.0 months. The 5- and 10-year OS were 47.2% (95% CI: 40.8–53.3%) and 39.6% (95% CI: 32.5–46.6%), respectively. Advanced age, dichotomized T-stage (T4a/b vs. T1–3), M-stage, and orbital involvement were significant poor prognostic factors on univariable analysis (p’s < 0.01). On multivariable analysis, orbital involvement (HR: 2.73, 95% CI: 1.42–5.27, p = 0.003) and distance metastasis stage (HR: 3.00, 95% CI: 1.25–7.21, p = 0.014) were both independently associated with worse OS. Conclusions: This observational study presents the largest multi-center cohort analysis of SNUC to date, providing new insights into prognostic factors for a rare cancer treated at global centers of excellence. Orbital involvement and the presence of metastases are candidate independent risk factors associated with poorer OS.